Relapse-free cure from multidrug-resistant tuberculosis in Germany

European Respiratory Journal

Volumn 51, Issue 2, 2018, Pages

  Heyckendorf, Jan ^a,b,c   Van Leth, Frank ^d   Kalsdorf, Barbara ^a,b,c   Olaru, Ioana D ^a,e   Günther, Gunar ^f   Salzer, Helmut J F ^a,b,c   Terhalle, Elena ^a,b,c   Rolling, Thierry ^b,g,h   Glattki, Georg ⁱ   Müller, Marius ^j   Schuhmann, Maren ^k   Avsar, Korkut ^l   Lange, Christoph ^a,b,c,m  

^a RESEARCH CENTER BORSTEL   (Germany)

^b German Center for Infection Research (DZIF) Clinical Tuberculosis Unit   (Germany)

^c UNIVERSITY OF LÜBECK   (Germany)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^f UNIVERSITY OF NAMIBIA   (Namibia)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

ⁱ Karl Hansen Klinik GmbH   (Germany)

^j Sankt Katharinen Krankenhaus   (Germany)

^k UNIVERSITY OF HEIDELBERG   (Germany)

^l ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

^m KAROLINSKA INSTITUTE   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BEDAQUILINE; CAPREOMYCIN; DELAMANID; ISONIAZID; LINEZOLID; MOXIFLOXACIN; QUINOLONE DERIVATIVE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

AGE DISTRIBUTION; ALGORITHM; ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; FOLLOW UP; GERMANY; HUMAN; INFORMED CONSENT; LETTER; MULTIDRUG RESISTANT TUBERCULOSIS; PATIENT CARE; PHENOTYPE; PRIORITY JOURNAL; SEX; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; CLINICAL TRIAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; LUNG TUBERCULOSIS; MULTICENTER STUDY; PROSPECTIVE STUDY; RECURRENT DISEASE; REMISSION;

ANTITUBERCULAR AGENTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FOLLOW-UP STUDIES; GERMANY; HUMANS; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 85044099167     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.02122-2017     Document Type: Letter

References (17)

1. European Commission. G20 Leaders' Declaration. Shaping an Interconnected World. European Commission Statement /17/1960. Hamburg, European Commission, 2017.
2. European Centre for Disease Prevention and Control (ECDC). Tuberculosis Surveillance and Monitoring in Europe 2016. Stockholm, European Centre for Disease Prevention and Control, 2017.
3. Olaru ID, Lange C, Heyckendorf J. Personalized medicine for patients with MDR-TB. J Antimicrob Chemother 2016; 71: 852-855.
4. Olaru ID, von Groote-Bidlingmaier F, Heyckendorf J, et al. Novel drugs against tuberculosis: a clinician's perspective. Eur Respir J 2015; 45: 1119-1131.
5. Pankhurst LJ, del Ojo Elias C, Votintseva AA, et al. Rapid, comprehensive, and affordable mycobacterial diagnosis with whole-genome sequencing: a prospective study. Lancet Respir Med 2016; 4: 49-58.
6. Votintseva AA, Bradley P, Pankhurst L, et al. Same-day diagnostic and surveillance data for tuberculosis via whole-genome sequencing of direct respiratory samples. J Clin Microbiol 2017; 55: 1285-1298.
7. Günther G, Lange C, Alexandru S, et al. Treatment outcomes in multidrug-resistant tuberculosis. N Engl J Med 2016; 375: 1103-1105.
8. World Health Organization. Definitions and Reporting Framework for Tuberculosis - 2013 Revision (Updated December 2014). WHO Library Cataloguing-in-Publication Data. Geneva, World Health Organization, 2014.
9. Horsburgh CR Jr, Barry CE III, Lange C. Treatment of tuberculosis. N Engl J Med 2015; 373: 2149-2160.
10. Lange C, Abubakar I, Alffenaar JW, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 2014; 44: 23-63.
11. Falzon D, Schunemann HJ, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J 2017; 49: 1602308.
12. Schaberg T, Bauer T, Castell S, et al. [Recommendations for therapy, chemoprevention and chemoprophylaxis of tuberculosis in adults and children. German Central Committee against Tuberculosis (DZK), German Respiratory Society (DGP)]. Pneumologie 2012; 66: 133-171.
13. Diacon AH, Van Baelen B, Theeuwes M. More on treatment outcomes in multidrug-resistant tuberculosis. N Engl J Med 2016; 375: 2609-2610.
14. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375: 1823-1833.
15. Kurbatova EV, Cegielski JP, Lienhardt C, et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respir Med 2015; 3: 201-209.
16. Guglielmetti L, Le Du D, Veziris N, et al. Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis? Eur Respir J 2016; 48: 582-585.
17. Olaru ID, Heyckendorf J, Andres S, et al. Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis. Eur Respir J 2017; 49: 1700742.